Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pd1y is a synthetic 20-amino acid peptide derived from the BC loop of the human Programmed Cell Death Protein 1 (PD-1) receptor. It functions as a competitive inhibitor of the PD-1/PD-L1 checkpoint by binding directly to Programmed Death-Ligand 1 (PD-L1), thereby preventing the interaction between PD-1 and PD-L1 that typically suppresses T-cell activation. Primarily utilized as a research reagent and a structural probe, pd1y has demonstrated the ability to restore T-cell proliferation and cytokine production in preclinical models. While it serves as a foundational molecule for the design of more stable peptide mimetics and small-molecule inhibitors in the field of cancer immunotherapy, it has not progressed into formal clinical trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pd1y.